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Abstract 
Opioid receptor activation was shown to enhance the efficacy of antineoplastic drugs in several 
human cancer cell lines. Especially in veterinary medicine, where side effects of chemotherapy 
are tolerated to a lesser extent and hence smaller doses are given, agents potentiating 
chemotherapeutic agents would be an optimal approach to treatment. Canine transitional cell 
carcinoma cells (TCC, K9TCC), canine osteosarcoma cells (OSA, Abrams) and canine 
hemangiosarcoma cells (HSA, DAL-4) were incubated with different combinations of 
methadone, buprenorphine and doxorubicin, in order to test inhibition of cell proliferation. 
Opioid receptor density was assessed with FACS in drug native and doxorubicin pretreated cells. 
In TCC and OSA cell lines opioid receptor density increased after doxorubicin pretreatment. In 
combination treatment, however, we did not find significant potentiation of doxorubicin’s 
inhibitory effect on proliferation in these cell lines. Neither was there a significant increase of the 
effect of doxorubicin when the opioids were added 24 hours before doxorubicin. Hence, we could 
not confirm the hypothesis that opioids increase the anti-proliferative effect of the anti-neoplastic 
drug doxorubicin in any of these canine tumors cell lines. The lack of effect on a cellular level 
does not warrant a clinical approach to use opioids together with doxorubicin in dogs with 
cancer. 
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Zusammenfassung 
Mittels Aktivierung von Opioidrezeptoren konnte der Effekt von Zytostatika auf verschiedene 
humane Tumorzelllinien erhöht werden. Da besonders in der Veterinärmedizin Chemotherapie-
bedingte Nebenwirkungen weniger toleriert und dadurch tiefere Chemotherapeutika-Dosen 
appliziert werden, wären Medikamente, welche die Antitumorwirkung von Zytostatika steigern, 
sehr hilfreich.   
Canine Übergangszellkarzinomzellen (TCC, K9TCC), canine Osteosarkomzellen (OSA, Abrams) 
und canine Hämangiosarkomzellen (HSA, DAL-4) wurden mit verschiedenen Kombinationen 
von Methadon, Buprenorphin und Doxorubicin inkubiert um die Zellwachstumshemmung zu 
untersuchen. Die Opioidrezeptordichte wurde mittels Durchflusszytometrie bei nativen und 
Doxorubicin-vorbehandelten Tumorzellen ermittelt. Bei TCC und OSA stieg die Dichte der 
Opioidrezeptoren nach Doxorubicin-Vorbehandung an. Allerdings zeigte sich in der 
Kombinationstherapie keine signifikante Potenzierung des inhibitorischen Effekts von 
Doxorubicin auf die Zellproliferation dieser drei Tumorzelllinien. Ebenso fand sich keine 
signifikante Steigerung des Doxorubicin-Effekts nach 24-stündiger Inkubation mit Methadon 
bzw. Buprenorphin vor Doxorubicinbehandlung.  
Wir konnten die Hypothese, Opioide verstärken die anti-proliferative Wirkung von Doxorubicin 
in diesen Tumorzellen, nicht bestätigen. Die mangelnde Wirksamkeit auf zellulärer Ebene 
rechtfertigt einen klinischen Versuchsansatz bei Hunden mit Krebs nicht. 
 
Schlüsselwörter: µ-Rezeptor, Buprenorphin, Krebs, Opioidrezeptor, Hunde,  
Durchflusszytometrie 
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Opioid receptor activation was shown to enhance the efficacy of anti-neoplastic drugs 
in several human cancer cell lines. In these cell lines, doxorubicin increased the number 
of opioid receptors and methadone concurrently enhanced cellular doxorubicin uptake. 
Triggered through lay press and media, animal owners started to challenge veterinary 
oncologists with questions about methadone use in anti-cancer therapy. Especially in 
veterinary medicine, where side effects of chemotherapy are tolerated to a lesser extent 
and hence smaller doses are given, agents potentiating chemotherapeutic agents would 
be an optimal approach to treatment. Canine transitional cell carcinoma cells (TCC, 
K9TCC), canine osteosarcoma cells (OSA, Abrams) and canine hemangiosarcoma cells 
(HSA, DAL-4) were incubated with different combinations of methadone, buprenor-
phine and doxorubicin, in order to test inhibition of cell proliferation. Opioid receptor 
density was assessed with fluorescence-activated cell sorting in drug native and doxoru-
bicin pretreated cells. In TCC and OSA cell lines opioid receptor density increased after 
doxorubicin pretreatment. In combination treatment, however, we did not find signifi-
cant potentiation of doxorubicin's inhibitory effect on proliferation in these cell lines. 
Neither was there a significant increase of the effect of doxorubicin when the opioids 
were added 24 hr before doxorubicin. Hence, we could not confirm the hypothesis that 
opioids increase the anti-proliferative effect of the anti-neoplastic drug doxorubicin in 
any of these canine tumour cell lines. The lack of effect on a cellular level does not war-
rant a clinical approach to use opioids together with doxorubicin in dogs with cancer.
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1  | INTRODUC TION
Oncologists continue to search for possibilities to enhance the effec-
tiveness of chemotherapeutic agents without adding toxicity to the 
patient. Recently, the opioid methadone was described to potentiate 
the pro-apoptotic effect of doxorubicin, a commonly used anti-neo-
plastic agent in human leukaemia and glioblastoma cells (HL-60, 
CEM, Tanoue, Reh, Nalm6, A172) in vitro Friesen, Bacher, Hormann, 
Roscher, and Miltner (2011); Friesen, Hormann, & Roscher, 2014; 
Friesen, Roscher, & Hormann, 2013; Singh, Jayanthan, & Farran, 2011) 
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Furthermore, the researchers showed also tumour-growth inhibitory 
properties in co-treated patient-derived acute lymphoblastic leukemia 
(ALL-SCID6) xenografts in vivo (mouse model) (Friesen et al., 2013). 
Two distinct mechanisms were proposed as chemo-enhancing prop-
erties: First, methadone increases the intracellular content and hence 
activity of doxorubicin even in drug-resistant tumour cells, secondly, 
doxorubicin increases opioid receptor expression in leukaemia cells 
(Friesen et al., 2013).
When these findings were spread publicly through lay press and 
media, cancer patients started to confront physicians and pharma-
cists, willing to use methadone in their cancer treatment (Theile & 
Mikus, 2018). Equally, animal owners started to challenge veterinary 
oncologists with questions about methadone use in anti-cancer ther-
apy. Some veterinarians even started to use the combination of meth-
adone with chemotherapy in cancer bearing dogs on clients’ request.
In animals or cancer cell lines of pet animals, the interaction of 
opioids with anti-neoplastic agents has not been investigated to 
date. In this study, we wanted to explore if opioid receptors can be 
found on canine tumour cells and whether an interaction of opi-
oids and doxorubicin can be observed. Methadone is a synthetic 
opioid agonist and binds to the opioid μ-receptor. The drug is reg-
ularly used in veterinary medicine, mostly for perioperative anal-
gesia and to relieve short- to intermediate-term painful conditions 
(Grimm, Lamont, Tanquilli, Greene, & Robertson, 2015; Ingvast-
Larsson, Holgersson, Bondesson, Lagerstedt, & Olsson, 2010). 
However, opioids in general underlie strict regulatory guidelines 
and their long-term use in an outpatient setting is not as common 
as in man.
Doxorubicin, an anthracycline antibiotic, is a frequently admin-
istered anti-neoplastic agent in veterinary medicine (Arcamone, 
Cassinelli, & Fantini, 1969; Arcamone, Cassinelli, & Franceschi, 1972; 
Withrow, Vail, & Page, 2013). Applied in various species, the dose 
of doxorubicin is limited to dosages of ≤30 mg/m2 due to mostly 
gastrointestinal and haematologic toxicity. Furthermore, a cumula-
tive dose of 120–150 mg/m2 can result in specific cardiac toxicity 
in dogs (Ogilvie, Richardson, & Curtis, 1989; Sparano, Gordon, Hall, 
Iatropoulos, & Noble, 1982; Vanvleet & Ferrans, 1980). While ini-
tially effective in many disease entities, over time, drug resistance 
will often occur (Shahi et al., 2015; Zandvliet, Teske, Schrickx, & Mol, 
2015; Zandvliet, Teske, & Schrickx, 2014). To overcome or reverse 
the resistance towards the drug or to enhance the efficacy of doxo-
rubicin without concurrently enhancing clinical side effects would 
be of great interest in veterinary medicine.
Under our first hypothesis, i.e. that canine tumour cells from 
various diseases express opioid receptors, we tested several canine 
cell lines (transitional cell carcinoma (TCC), osteosarcoma (OSA) and 
hemangiosarcoma (HSA)) by flow cytometric analysis before and 
after doxorubicin exposure. Next, we tested if the concurrent use of 
opioids in canine tumour cell lines in vitro enhances effects of doxo-
rubicin, measured with proliferation assay. The resulting data will be 
used for future decisions on whether opioids should be investigated 
deeper with an aim of a possible use in a clinical setting in dog cancer 
patients with specific neoplastic conditions receiving doxorubicin.
2  | MATERIAL S AND METHODS
First, presence and expression of opioid receptors on canine transi-
tional cell carcinoma, canine osteosarcoma and canine cells heman-
giosarcoma before and after the treatment with doxorubicin was 
investigated through flow cytometry. Then, different dosages of doxo-
rubicin, methadone and buprenorphine were tested on all three cell 
lines. Afterwards, the selected doses were used for different drug com-
binations, which were examined by means of a cell proliferation assay.
2.1 | Drugs and reagents
Methadone hydrochloride (Methadon Streuli®) was obtained from 
Streuli Pharma AG (Uznach, Switzerland) and buprenorphine hydro-
chloride (Temgesic®) was obtained from Indivior Schweiz AG (Baar, 
Switzerland). Both are aqueous solutions in disposable ampoules. 
For each experiment a new ampoule was opened.
Doxorubicin hydrochloride (Adriblastin® RD/-Solution) was ob-
tained from Pfizer AG (Zürich, Switzerland). Each vial was used three 
to six times and stored at 4°C for a maximum of 3 weeks. Adriblastin 
is an aqueous solution.
Naloxone fluorescein acetate was obtained from Tocris, Bio-
Techne (Zug, Switzerland) and was dissolved in dimethylsulfoxide.
2.2 | Cell lines
Canine transitional cell carcinoma cells (K9TCC) was obtained 
from Prof. Knapp, Purdue (PU, Indiana, USA), canine osteosarcoma 
cell (Abrams) were obtained from Prof. Rebhurn, (UCD, California, 
USA) and canine hemangiosarcoma cells (DAL-4) were obtained 
from Kerafast Inc. (Massachusetts, USA). The K9TCC and Abrams 
cells were grown in Dulbecco's modified eagle's medium (Gibco™) 
containing 10% fetal bovine serum (FBS) (Gibco™), 100 units/ml of 
penicillin (Gibco™), 100 μg/ml of streptomycin (Gibco™) and 10 mM of 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid buffer (Gibco™) 
and incubated at 5% CO2 and 37°C. The three cell lines are described 
as TCC (transitional cell carcinoma, K9TCC), OSA (osteosarcoma, 
Abrams) and hemangiosarcoma (HSA, DAL-4) in figures and text.
The DAL-4 cells were grown in Ham F-12 (Gibco™) containing 
10% FBS (Gibco™), 100 μg/ml of primocin, 0.05 mg/ml of endothe-
lial cell growth supplement, 0.1 mg/ml of heparin (Sigma-Aldrich®), 
10 mM of HEPES buffer (Gibco™) and incubated at 37°C in 5% CO2 
humidified incubator. All cell lines were free of mycoplasma.
2.3 | Detection of opioid receptors
Cells were incubated for 72 hr with either doxorubicin or saline. The con-
centration of doxorubicin was 0.5 μg/ml for TCC, 0.15 μg/ml for OSA and 
0.05 μg/ml for HSA. The cells were trypsinized, centrifuged and resus-
pended in PBS/1% FBS containing naloxone fluorescein acetate (0.05nM). 
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The cells were incubated for 30 min at RT in darkness. After incubation 
the cells were washed, centrifuged and resuspended in cold PBS/1% FBS. 
CytoFLEX S flow cytometer (Institute of Virology, Vetsuisse Faculty of the 
University of Zurich, Switzerland) was used for the flow cytometer analy-
sis. The flow cytometry results were analysed by FlowJo 10.6.1 software.
2.4 | Proliferation assay
The proliferation assay was performed with the cell count-
ing kit CCK-8 according to the manufacturer's protocol (Dojindo 
Laboratories, Kumamoto, Japan). CCK-8 reagent is a ready for use 
solution, which allows determination of the number of viable cells in 
proliferation assays. Five hundred cells for OSA and TCC cells, and 
2000 cells for HSA cells per well were seeded into 96-well plates. For 
initial dose finding, cells were treated with 10, 5 and 1 μg/ml of meth-
adone, 0.2, 0.5, 1 μg/ml of buprenorphine and 0.5, 0.1, 0.05, 0.015, 
0.01, 0.005 μg/ml of doxorubicin. The cells were incubated up to 
72 hr and the proliferation was measured at time points of 0, 24, 48 
and 72 hr. At each time point, 10 μl of the CCK-8 solution was given 
to the corresponding wells and the absorbance was measured 4 hr 
later at 450 and 600 nm using microplate reader Epoche 2 (BioTek).
For the combination studies, methadone or doxorubicin was added 
to cells for 24 hr prior to adding the combination compound doxorubicin 
and methadone, respectively. The concentrations and order of the com-
pound addition for each cell line are indicated in the figure legend. The 
cell proliferation was measured 72 hr after adding the first compound.
2.5 | Statistical analysis
Statistical analyses were performed using R (The R Foundation for 
Statistical Computing, version 3.6.0, 2019) along with the multcomp 
package (version 1.4–10) for post-hoc tests. For the detection of 
opioid receptors by fluorescence-activated cell sorting, two-tailed 
unpaired Student t-tests with the Welch–Satterthwaite approxima-
tion were used (see Figure 1). The analysis of the data obtained from 
proliferation assays was done with one-way ANOVA. In the combi-
nation study, Tukey's range test was used for pairwise comparison of 
the four factor levels (see Figure 2 and Figure S3). In the dose find-
ing study, the three respective doses were compared to the control 
using Dunnett's test at each time point and for each compound (see 
Figure S2). p values below .05 were considered statistically signifi-
cant and denoted with a star (*). Two stars (**) were used for p values 
below 0.01 and three stars (***) were used for p values falling below 
0.001.
3  | RESULTS
3.1 | Expression of opioid receptor in canine cancer 
cell lines
First, we investigated the presence and expression of opioid re-
ceptors on canine transitional cell carcinoma, canine osteosarcoma 
and canine hemangiosarcoma cells through flow cytometry. Flow 
cytometry revealed receptors on all three tested cell lines. In all 
tested cell lines, 35%–80% of the cells expressed opioid receptors 
in untreated cells (Figure S1). After incubation with doxorubicin for 
72 hr TCC and OSA increased opioid receptor expression almost 
twofold, to over 90%, which was significantly higher than in the 
control group (Figure 1). HSA showed no significant enhancement 
of the receptor density after doxorubicin treatment (Figure 1).
3.2 | Effects of different opioid and doxorubicin 
concentrations on canine cancer cell line proliferation
We tested anti-proliferative effects of increasing doses of metha-
done or buprenorphine and doxorubicin on the three cell lines in 
F I G U R E  1   Effect of pretreatment with Doxorubicin on opioid receptor expression in canine transitional cell carcinoma (TCC), canine 
osteosarcoma Abrams (OSA) and canine hemangiosarcoma DAL-4 (HSA). Mean ± SD of three experiments performed independently is 
shown
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order to determine the optimal concentration for the combinato-
rial experiments. Methadone and buprenorphine did not inhibit cell 
proliferation of all cell lines tested up to concentration of 10 μg/ml 
and 1 μg/ml, respectively (Figure S2a and b). Doxorubicin had strong, 
concentration dependent, inhibitory effect on cell proliferation in 
all three cell lines tested (Figure S2c). The cell lines, however, were 
unequally sensitive towards doxorubicin: the approximately 50% in-
hibitory concentration at 48 hr was highest in TCC with 0.500 μg/ml, 
fivefold lower in OSA (0.100 μg/ml) and 33.3-fold lower in HSA cell 
lines (0.015 μg/ml). We then chose the dose of each compound for 
the combinatorial experiments (Table 1 and 2). The chosen concen-
trations should only minimally inhibit cell proliferation alone, in order 
to be able to observe the effects of combinations. Furthermore, the 
applied dose had to fulfill the criterion to potentially produce clini-
cally achievable plasma levels in dogs. Based on our findings (Figure 
S2a and b), we selected the same opioid dose for all cell lines to be 
used in combination experiments.
3.3 | Drug combinations show no potentiation of 
anti-proliferative effect
When the cells were pretreated with doxorubicin and methadone 
was added 24 hr later, we did not find a potentiation of doxorubicin's 
inhibitory effect on proliferation in TCC, OSA or HSA cell lines 
(Figure 2a). Pretreatment with methadone for 24 hr did not enhance 
the cytotoxic effect of doxorubicin either (Figure 2b). Similar to 
methadone, combination of doxorubicin and buprenorphine did not 
result in enhanced anti-proliferative effect in any of the combina-
tions tested, irrespective if doxorubicin or buprenorphine was added 
first (Figure S3a and b).
4  | DISCUSSION
The opioid methadone recently gained much attention as an anti-
neoplastic compound, possibly potentiating in vitro and in vivo ef-
ficacy of doxorubicin (Friesen, Roscher, Alt, & Miltner, 2008; Friesen 
et al., 2013; Singh et al., 2011). The effects, however, were not con-
stantly shown. From a pharmacological point of view, the in vitro 
F I G U R E  2   Combination of methadone and doxorubicin does not result in enhanced cancer cell growth inhibition in canine transitional 
cell carcinoma (TCC), canine osteosarcoma Abrams (OSA) and canine hemangiosarcoma DAL-4 (HSA). Cells pretreated with doxorubicin 
first (a) and methadone first (b) were incubated for 72 hr and cell viability was measured. Mean ± SD of three experiments performed 
independently is shown
TA B L E  1   Doses of methadone and doxorubicin for experiments
 Methadone Doxorubicin
Transitional cell carcinoma 
(K9TCC)
3 μg/ml 0.500 μg/ml
Osteosarcoma (Abrams) 3 μg/ml 0.100 μg/ml
Hemangiosarcoma (DAL-4) 3 μg/ml 0.015 μg/ml
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anti-neoplastic effects mostly occurred at unrealistic clinical dose 
levels and the mode of action in terms of receptors and pathways 
is unclear (Brawanski et al., 2018; Theile & Mikus, 2018). In addi-
tion, no randomized, controlled and well-powered clinical studies on 
a possible anti-neoplastic efficacy of methadone are available. The 
few retrospective investigations show no impact on progression-
free survival or overall survival on cancers with glioblastoma mul-
tiforme (Onken, Friesen, Vajkoczy, & Misch, 2017) or other cancers 
(Reddy, Schuler, & Cruz, 2017). It is of note that for human cancer 
patients, methadone is neither approved nor recommended as an 
anti-cancer treatment. Various specialist associations reject the use 
of methadone as an antitumour treatment from a medical and ethical 
point of view (Kreye, Masel, Hackner, Stich, & Nauck, 2018).
In this study the number of opioid receptors was moderate and 
increased after doxorubicin exposure in the canine TCC and OSA, 
but not in the HSA cell line. Cell lines with high opioid receptor den-
sity such as human leukaemia cells were found to respond stron-
ger to methadone or combination treatment than cells with only 
moderate opioid receptor expression (Friesen et al., 2008, 2013). 
The receptor density could be cell line or even patient-specific. 
In terms of direct growth inhibition by opioids, some established 
tumour cell lines showed increased apoptosis at low methadone 
concentrations of 1 μg/ml, together with temozolomide. In oth-
ers, cell lines derived from human glioblastoma multiforme-patient 
samples, had no significant quantitative differences in the μ-opioid 
receptor expression, and only a decrease of cell viability in a higher 
dose-dependent range (15–45 μg/ml) was found (Brawanski et al., 
2018). In another cell culture model also high doses of methadone 
(10–30 μM, about 3-–μg/ml) were needed to reduce glioblastoma 
cell viability (Oppermann, Matusova, & Glasow, 2019). Various 
doses of methadone did not affect cell viability of melanoma cell 
lines grouped into μ-opioid receptor density (OPRM1 high, medium, 
negative). The concurrent cisplatin and methadone treatment re-
sulted in a slightly decreased cell viability of 10%–20% in the high 
receptor-dense cells. The effect, however, could not be reproduced 
with temozolomide as anti-neoplastic agent (Bruggen, Mangana, & 
Irmisch, 2018).
We could, however, not confirm the hypothesis that opioids in-
crease the potency of doxorubicin in any of the three investigated 
cancer cell lines of dogs. Comparably, no anti-neoplastic effect was 
observed in several established and primary human glioblastoma 
cell lines using combinations of methadone with temozolomide 
(Brawanski et al., 2018), irradiation or both (Oppermann et al., 2019). 
A reasonable concentration of methadone in cell line conditions, 
which can be reached using clinically tolerable dosage in man is 
around 0.3–1.3 μg/ml (Brawanski et al., 2018; Inturrisi, Colburn, 
Kaiko, Houde, & Foley, 1987). For our experiments, we chose the 
dose of methadone (3 μg/ml) and buprenorphine (0.5 μg/ml) in 
slightly higher range (Abbo, Ko, & Maxwell, 2008; Ingvast-Larsson 
et al., 2010), and verified that the chosen dose did not inhibit tumour 
cell proliferation. A direct inhibition of cell proliferation by meth-
adone with increasing doses is possible, but was only observed at 
doses higher than 3 μg/ml, around 10 μg/ml (Brawanski et al., 2018; 
Friesen et al., 2013; Oppermann et al., 2019).
We selected the herein used three dog cell lines of low, mod-
erate and high sensitivity to doxorubicin treatment. As clinical 
diseases in dogs, hemangiosarcoma and osteosarcoma are treated 
with doxorubicin as a single agent or in combination with other an-
ti-neoplastic drugs (Kent, Strom, London, & Seguin, 2004; Mauldin, 
Matus, Withrow, & Patnaik, 1988; Ogilvie, Powers, Mallinckrodt, 
& Withrow, 1996; Sorenmo, Jeglum, & Helfand, 1993). The former 
cell line shows high sensitivity and the latter moderate sensitivity 
(fivefold less than hemangiosarcoma) towards growth inhibition 
with doxorubicin. Transitional cell carcinomas in the dog are usu-
ally not treated with doxorubicin in a clinical setting and showed 
lowest sensitivity as a cell line (33-fold less than hemangiosarcoma) 
(Arnold, Childress, & Fourez, 2011; Marconato et al., 2011; Shapiro, 
Kitchell, Fossum, Couto, & Theilen, 1988). Inhibition of individual 
cell line's proliferation by doxorubicin was measured 48 hr after 
treatment start to reveal concentration that inhibits the cells by 
50%–70%.
Buprenorphine was used as a second opioid to test. The oral 
bioavailability of methadone in dogs is described to be below de-
tection, owing to the first pass effect (Kukanich, Kukanich, & 
Rodriguez, 2011; Kukanich, Lascelles, Aman, Mealey, & Papich, 
2005). Buprenorphine applied transmucosally, on the contrary, has 
a bioavailability between 38% and 47%, which could be useful and 
convenient for an outpatient setting. Because opioids as methadone 
and buprenorphine are bound to the strict federal law of narcotics, 
an outpatient trial would only be possible if the opioids can be given 
orally or transmucosally.
The cell lines used in this study express moderate amounts of 
opioid receptors, and its expression increased to over 90% after 
72 hr of incubation with doxorubicin in the transitional carcinoma 
and the osteosarcoma cell line. Nevertheless, no positive or neg-
ative effect on cell proliferation could be observed after co-treat-
ment with opioids. Friesen et al. (2011, 2013, 2014) suspected the 
effect of methadone to be achieved by the μ-receptor activation on 
tumour cells, with an unknown mechanism. The expression levels 
of the classical opioid receptor were assessed through an indirect 
approach with the fluorescein-labeled naloxone. This is a limitation 
in our approach, as we neither provide a direct, for example anti-
body-based evaluation of μ-opioid receptor, nor provide evidence 
of functionality of μ-receptors with overexpression or knock-down. 
Naloxone is a non-selective opioid antagonist and could have bound 
any opioid receptor in flow cytometry. In the worst case, the specific 
absence of the μ-receptor could even have been a possible reason 
TA B L E  2   Doses of buprenorphine and doxorubicin for 
experiments
 Buprenorphine Doxorubicin
Transitional cell carcinoma 
(K9TCC)
0.5 μg/ml 0.500 μg/ml
Osteosarcoma (Abrams) 0.5 μg/ml 0.100 μg/ml
Hemangiosarcoma (DAL-4) 0.5 μg/ml 0.015 μg/ml
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why in our study opioids and doxorubicin combination treatment 
showed no benefit. Furthermore, other receptors could be involved 
in sensitization or induction of apoptosis by opioids (Li, Li, & Zhang, 
2010; Yin, Mufson, Wang, & Shi, 1999).
However, along with the findings of our colleagues from human 
medicine (Brawanski et al., 2018; Bruggen et al., 2018; Inturrisi et al., 
1987; Kreye et al., 2018; Oppermann et al., 2019; Theile & Mikus, 
2018) we cannot advocate the clinical use of opioids to enhance 
doxorubicin's efficacy in dogs with tumours. While we found an in-
crease in opioid receptors in TCC and OSA, none of the combination 
treatments indicated additional inhibition of cellular proliferation. 
Furthermore, also in dogs, opioids and specifically methadone as a 
long-term treatment can have considerable side effects such as inap-
petence, nausea, constipation (Frey & Löscher, 2010). Additional side 
effects could have a massive impact on quality of life of dog patients 
undergoing chemotherapy.
5  | CONCLUSIONS
The lack of effect on a cellular level does not warrant a clinical ap-
proach to use opioids together with doxorubicin in dogs with cancer. 
In case of further pursuit of such combined approach it should be 
proactively considered to use an orally bioavailable variant such as 
buprenorphine.
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